The Schedule Dependent Combination Of Bortezomib (Bor) With Rituximab (R), Cyclophosphamide (C) And Prednisone (P) Produces Minimal Toxicity, Even At Relatively High Doses Of Proteasome Inhibitor, In Patients With Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John F. Gerecitano,Carol S. Portlock,Ariela Noy,Paul A. Hamlin,Craig H. Moskowitz,David Straus,Steven M. Horwitz,Maria Lia Palomba, Otilia-Liana Dumitrescu,Jennifer Pappanicholaou,Ellen Neylon,Rachel Hamelers,Andrew D. Zelenetz,Thomas J. Myers,Anthony Boral,Owen A. O’Connor

BLOOD（2006）

引用 4|浏览27

暂无评分

摘要

Phase II studies have established the efficacy of single agent Bor in patients with B-cell non-Hodgkin's Lymphoma (NHL). We sought to determine the safety and efficacy of combining Bor with a modified R-CVP chemotherapy regimen (omitting vincristine). The rationale for this regimen includes:

查看译文

关键词

proteasome inhibitor,cyclophosphamide,bortezomib,b-cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要